Roland Walter

Adjunct Professor, Epidemiology
Professor, Medicine - Hematology
Adjunct Professor, Laboratory Medicine and Pathology



MD Medicine, University of Zurich (Switzerland), 1997
PhD Experimental Pathology, University of Washington, 2006
MS Epidemiology (Clinical Research), University of Washington, 2011



Fred Hutchinson Cancer Research Center
100 Fairview Ave. N., D2-190
Seattle, WA 98109
View Website »


My research is focused on acute myeloid leukemia (AML). I am particularly interested in improving antibody-based therapies, both by optimizing the efficacy/safety profile of existing therapeutics and through the preclinical and early clinical development of novel antigen-directed immunotherapies. As examples of latter efforts, my lab has contributed to candidate drug identification and preclinical development of 5 novel agents that have subsequently advanced to clinical testing (SGN-CD33A, SGN-CD123A, AMG 330, AMV-564, and APVO436). A major area of focus of our research lies in the delineation of the mechanisms of action and resistance that are relevant for antibody-based AML therapeutics and the rational development of combination therapies that can overcome drug resistance. Many of my studies conducted over the last 15+ years have aimed at optimizing CD33-targeted and, more recently, CD123-targeted therapies. In clinical studies, I conduct trials testing novel treatments and innovative care approaches for AML patients. Furthermore, in collaborative research, I use large patient datasets to develop and improve diagnostic and prognostic tools for people with AML.

Research Areas

Research Interests

  • Acute myeloid leukemia
  • CD33
  • Immunotherapy of AML
  • Clinical trials in AM
  • Measurable residual disease (MRD)
  • Predictive modeling

Recent Publications (PubMed)

Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.
(2023 Mar 20)
Leuk Lymphoma
Cassaday RD, Zarling LC, Garcia KA, Sala-Torra O, Stevenson PA, Martino CH, Liu YJ, Fang M, Percival MM, Halpern AB, Becker PS, Oehler VG, Shustov AR, Cooper JP, Orozco JJ, Hendrie PC, Walter RB, Radich JP, Soma LA, Estey EH

Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.
(2023 Mar 9)
Leuk Lymphoma
Kopmar NE, Gooley T, Curley N, Russell K, Shaw C, Schonhoff K, Lim J, Halpern AB, Walter RB, Scott BL, Appelbaum J, Hendrie PC, Estey EH, Percival MM

Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents.
(2023 Mar 8)
Leuk Lymphoma
Zhang MY, Othus M, Shaw C, Schonhoff KG, Halpern AB, Appelbaum J, Hendrie PC, Walter RB, Estey EH, Percival MM

Multiplex Base Editing to Protect from CD33-Directed Therapy: Implications for Immune and Gene Therapy.
(2023 Feb 23)
Borot F, Humbert O, Newby GA, Fields E, Kohli S, Radtke S, Laszlo GS, Mayuranathan T, Ali AM, Weiss MJ, Yen JS, Walter RB, Liu DR, Mukherjee S, Kiem HP

Invasive Fungal Infections After CLAG-M/CLAG Chemotherapy for Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms.
(2023 Feb 15)
Blood Adv
Lindsay J, Walti CS, Halpern AB, Xie H, Chung EL, Schonhoff KG, Huebner EM, Cheng GS, Kimball L, Leisenring WM, Greenwood M, Chen SC, Kong DC, Slavin MA, Boeckh M, Fredricks D, Liu C, Pergam SA, Walter RB, Hill JA

Show complete publication list

In the News

No news articles at this time.